Ardent Health (NYSE:ARDT) Price Target Cut to $12.00 by Analysts at JPMorgan Chase & Co.

Ardent Health (NYSE:ARDT) had its target price cut by JPMorgan Chase & Co. from $15.00 to $12.00 in a research report sent to investors on Monday,Benzinga reports. They currently have a neutral rating on the stock.

A number of other brokerages also recently commented on ARDT. Truist Financial reduced their price objective on Ardent Health from $21.00 to $13.00 and set a “buy” rating on the stock in a research report on Friday, November 14th. Stephens cut their price target on shares of Ardent Health from $21.00 to $17.00 and set an “overweight” rating on the stock in a research note on Friday, November 14th. UBS Group initiated coverage on Ardent Health in a research report on Wednesday, September 10th. They set a “buy” rating and a $17.00 price objective for the company. The Goldman Sachs Group started coverage on Ardent Health in a report on Tuesday, October 14th. They issued a “neutral” rating and a $19.00 price target for the company. Finally, Wall Street Zen cut Ardent Health from a “buy” rating to a “hold” rating in a research report on Sunday. Six equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $15.00.

Ardent Health Stock Down 0.1%

ARDT stock opened at $8.93 on Monday. The company has a market capitalization of $1.28 billion, a P/E ratio of 6.16, a price-to-earnings-growth ratio of 7.34 and a beta of 0.44. The firm’s fifty day simple moving average is $13.26 and its 200-day simple moving average is $13.15. Ardent Health has a 12 month low of $8.28 and a 12 month high of $17.34. The company has a debt-to-equity ratio of 0.67, a current ratio of 2.08 and a quick ratio of 1.95.

Ardent Health (NYSE:ARDT) last announced its quarterly earnings results on Wednesday, November 12th. The company reported $0.52 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.42 by $0.10. Ardent Health had a return on equity of 19.02% and a net margin of 3.24%.The company had revenue of $1.58 billion during the quarter, compared to the consensus estimate of $1.55 billion. Ardent Health has set its FY 2025 guidance at 0.850-1.030 EPS. As a group, equities research analysts forecast that Ardent Health will post 1.23 earnings per share for the current year.

Institutional Trading of Ardent Health

Large investors have recently made changes to their positions in the stock. Dynamic Technology Lab Private Ltd purchased a new stake in Ardent Health in the 1st quarter worth approximately $469,000. SageView Advisory Group LLC purchased a new stake in shares of Ardent Health during the 1st quarter valued at about $2,327,000. Strs Ohio purchased a new position in shares of Ardent Health in the first quarter valued at $494,000. Vanguard Group Inc. increased its position in shares of Ardent Health by 368.9% during the first quarter. Vanguard Group Inc. now owns 1,330,635 shares of the company’s stock worth $18,296,000 after acquiring an additional 1,046,845 shares during the last quarter. Finally, Trexquant Investment LP acquired a new stake in shares of Ardent Health during the first quarter worth approximately $1,537,000.

About Ardent Health

Ardent Health Partners, Inc owns and operates a network of hospitals and clinics that provides a range of healthcare services in the United States. It operates acute care hospitals, including rehabilitation hospitals and surgical hospitals. The company was founded in 2001 and is based in Brentwood, Tennessee.